Last update 21 Nov 2024
HRS-5965
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms HRS 5965, HRS5965 |
Target |
Mechanism CFB modulators(Complement factor B modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
18
Clinical Trials associated with HRS-5965Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study of Multiple Doses of HRS-5965 Capsules in Healthy Subjects and a Phase I Clinical Trial of the Effect of HRS-5965 on QT Interval in Healthy Subjects
A Single-dose, Open-label, Phase I Study Comparing the Pharmacokinetics, Safety, and Pharmacodynamics of HRS-5965 in Subjects With Mild and Moderate Hepatic Impairment and Normal Hepatic Function
A Multicenter, Randomized, Open-label, Active-comparator Controlled Phase III Study to Evaluate the Efficacy and Safety of HRS-5965 Capsule in Patients With Paroxysmal Nocturnal Hemoglobinuria
100 Clinical Results associated with HRS-5965
Login to view more data
100 Translational Medicine associated with HRS-5965
Login to view more data
100 Patents (Medical) associated with HRS-5965
Login to view more data
100 Deals associated with HRS-5965
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hemoglobinuria, Paroxysmal | Phase 3 | CN | 23 Oct 2024 | |
| Glomerulonephritis, IGA | Phase 2 | CN | 19 Dec 2023 | |
| C3 glomerulopathy | Phase 1 | CN | 08 Oct 2022 | |
| Glomerular disease | Phase 1 | CN | 08 Oct 2022 | |
| Idiopathic Membranous Glomerulonephritis | Phase 1 | CN | 08 Oct 2022 | |
| Lupus Nephritis | Phase 1 | CN | 08 Oct 2022 | |
| Anemia, Hemolytic | Phase 1 | - | - | |
| Atypical Hemolytic Uremic Syndrome | IND Approval | CN | 10 Mar 2023 | |
| Cold Agglutinin Disease | IND Approval | CN | 10 Mar 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | HRS-5965 50 mg BID | skqsymktsq(abczncmmay) = iygrydffin qbnqomyyft (anubjlnequ ) View more | - | 08 Dec 2024 | ||
HRS-5965 75 mg BID | skqsymktsq(abczncmmay) = kqqlwmdvgb qbnqomyyft (anubjlnequ ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free